These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 25670403)

  • 21. Meningococcal vaccine for infants?
    Campos-Outcalt D
    J Fam Pract; 2012 Aug; 61(8):482-4. PubMed ID: 22871657
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MenB vaccination programme will 'save lives'.
    Nurs Child Young People; 2015 Oct; 27(8):6. PubMed ID: 26448104
    [No Abstract]   [Full Text] [Related]  

  • 23. Prevention of group B meningococcal disease by vaccination: a difficult task.
    Thomas M
    N Z Med J; 2004 Aug; 117(1200):U1016. PubMed ID: 15475986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The challenge of post-implementation surveillance for novel meningococcal vaccines.
    Snape MD; Medini D; Halperin SA; DeTora L; Drori J; Moxon ER
    Vaccine; 2012 May; 30 Suppl 2():B67-72. PubMed ID: 22230578
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain.
    Larrauri A; Cano R; García M; Mateo Sd
    Vaccine; 2005 Jul; 23(32):4097-100. PubMed ID: 15908059
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recommendation of the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MenACWY-D) among children aged 9 through 23 months at increased risk for invasive meningococcal disease.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 Oct; 60(40):1391-2. PubMed ID: 21993344
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cross sectional survey of meningococcal C immunisation in children looked after by local authorities and those living at home.
    Hill CM; Mather M; Goddard J
    BMJ; 2003 Feb; 326(7385):364-5. PubMed ID: 12586668
    [No Abstract]   [Full Text] [Related]  

  • 28. Immunisation against meningococcus B.
    Blewitt J
    Lancet; 2013 Sep; 382(9895):857-8. PubMed ID: 24012267
    [No Abstract]   [Full Text] [Related]  

  • 29. Meningococcal group C vaccine and the United Kingdom experience.
    Salisbury D
    Int J Clin Pract Suppl; 2001 Feb; (118):10-1. PubMed ID: 11715358
    [No Abstract]   [Full Text] [Related]  

  • 30. Health economics of a hexavalent meningococcal outer-membrane vesicle vaccine in children: potential impact of introduction in the Dutch vaccination program.
    Bos JM; Rümke HC; Welte R; Postma MJ; Jager JC
    Vaccine; 2001 Oct; 20(1-2):202-7. PubMed ID: 11567765
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness analysis of a universal infant immunization program with meningococcal C conjugate vaccine in Brazil.
    de Soarez PC; Sartori AM; de Andrade Lagoa Nóbrega L; Itria A; Novaes HM
    Value Health; 2011 Dec; 14(8):1019-27. PubMed ID: 22152170
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluating Vaccination Programs That Prevent Diseases With Potentially Catastrophic Health Outcomes: How Can We Capture the Value of Risk Reduction?
    Mauskopf J; Masaquel C; Huang L
    Value Health; 2021 Jan; 24(1):86-90. PubMed ID: 33431158
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States.
    Shepard CW; Ortega-Sanchez IR; Scott RD; Rosenstein NE;
    Pediatrics; 2005 May; 115(5):1220-32. PubMed ID: 15867028
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adolescents need a booster of serogroup C meningococcal vaccine to protect them and maintain population control of the disease.
    Pollard AJ; Green C; Sadarangani M; Snape MD
    Arch Dis Child; 2013 Apr; 98(4):248-51. PubMed ID: 23482919
    [No Abstract]   [Full Text] [Related]  

  • 35. Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use - Advisory Committee on Immunization Practices (ACIP), 2010.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 Mar; 59(9):273. PubMed ID: 20224545
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis.
    De Wals P; Coudeville L; Trottier P; Chevat C; Erickson LJ; Nguyen VH
    Vaccine; 2007 Jul; 25(29):5433-40. PubMed ID: 17560695
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccinating first-year college students living in dormitories for Meningococcal disease: an economic analysis.
    Scott RD; Meltzer MI; Erickson LJ; De Wals P; Rosenstein NE
    Am J Prev Med; 2002 Aug; 23(2):98-105. PubMed ID: 12121797
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Economic analysis of the 1992-1993 mass immunization campaign against serogroup C meningococcal disease in Quebec.
    De Wals P; Erickson L
    Vaccine; 2002 Jun; 20(21-22):2840-4. PubMed ID: 12102036
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A meningococcal vaccine for infants.
    Med Lett Drugs Ther; 2013 Nov; 55(1429):92. PubMed ID: 24220580
    [No Abstract]   [Full Text] [Related]  

  • 40. New meningococcal vaccines in the UK.
    Lloyd KE; Paul SP; Garg AK
    Community Pract; 2015 Nov; 88(11):28-30, 33. PubMed ID: 26749613
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.